Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CI-994 is an inhibitor of histone deacetylase 1 (HDAC1), HDAC2, and HDAC3 (IC50s = 0.9, 0.9, and 1.2 µM, respectively).1 It is selective for these HDACs over HDAC8 (IC50 = >20 µM). CI-994 inhibits the growth of HCT116 colon cancer cells but not human mammary epithelial cells (HMECs; IC50s = 4 and >50 µM, respectively). In vivo, CI-994 (11.85 mg/kg twice per day) increases survival time in a rat model of 9,10-dimethyl-1,2-benzathracene-induced leukemia.2 It reduces tumor growth in an LNCaP mouse xenograft model, as well as in a Panc02 murine pancreatic cancer model.3 CI-994 (1, 10, and 30 mg/kg) reduces neutrophil accumulation, inflammatory cytokine expression, and neuronal loss in a mouse model of spinal cord injury.4
WARNING This product is not for human or veterinary use.
1. Novel aminophenyl benzamide-
2. Acetyldinaline: A new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells—preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. 53(13), 3008-3014 (1993).
3. Preclinical antitumor activity of CI-
4. Class I histone deacetylase (HDAC) inhibitor CI-